Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

November 21, 2018

LEO Pharma, PellePharm form $760m rare skin disease collaboration

LEO Pharma and PellePharm have entered into a development and commercialization collaboration to address unmet medical needs in various skin diseases like Gorlin Syndrome and High Frequency Basal Cell Carcinoma (BCC).

LEO Pharma, PellePharm form $760m rare skin disease collaboration